证券代码：603717 证券简称：天域生物 天域生物科技股份有限公司 募集资金使用可行性分析报告 二〇二五年八月 本可行性分析报告中如无特别说明，相关用语具有与《天域生物科技股份有 限公司 2025 年度向特定对象发行 A 股股票预案》中相同的含义。公司拟申请向 特定对象发行股票，现将本次发行募集资金投资项目可行性分析说明如下： 一、本次向特定对象发行股票募集资金的使用计划 本次向特定对象发行 A 股股票数量原拟定为不超过 80,417,610 股（含本数）， 募集资金总额原拟定为不超过人民币 52,673.53 万元（含本数），考虑到公司拟 继续使用不超过人民币 6,150 万元的闲置前次募集资金暂时补充公司流动资金， 扣除该部分流动资金影响后，本次向特定对象发行 A 股股票数量确定为不超过 并以中国证监会关于本次发行的注册批复文件为准。本次发行所募集资金在扣除 相关发行费用后将全部用于补充流动资金和偿还债务。 本次发行募集的资金将全部用于补充流动资金及偿还债务，有利于公司积极 健康的发展，进而提高上市公司的整体盈利能力。 截至 2025 年 3 月 31 日，公司资产负债率为 75.91%，超过同行业上市 ...

证券代码：603717 证券简称：天域生物 公告编号：2025-063 公司本次向特定对象发行 A 股股票预案披露事项不代表审批机关对本次向 特定对象发行 A 股股票相关事项的实质性判断、确认或批准，本次向特定对象 发行 A 股股票相关事项的生效和完成尚需公司股东大会审议通过、上海证券交 易所审核通过及中国证监会作出同意注册决定后方可实施。敬请广大投资者注意 投资风险。 特此公告。 天域生物科技股份有限公司董事会 天域生物科技股份有限公司（以下简称"公司"）于 2025 年 08 月 25 日分 别召开第四届董事会第四十三次会议、第四届监事会第三十六次会议，审议通过 了《关于 <公司 a="A" ensp="ensp" 年度向特定对象发行="年度向特定对象发行" 股股票预案="股股票预 案"> 的议案》及其他相关议 案。具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）上披露 的《天域生物科技股份有限公司 2025 年度向特定对象发行 A 股股票预案》，敬 请广大投资者注意查阅。 天域生物科技股份有限公司 关于 2025 年度向特定对象发行 A 股股票预案 披露的提示性公告 本公司董事 ...

Group 1 - The company plans to issue shares to a specific group, aiming to enhance its capital structure and improve financial stability [3][4][26] - The issuance is driven by high debt levels and the need for liquidity, with the company's debt-to-asset ratio reaching 75.91% as of March 31, 2025 [4][5][6] - The actual controller's confidence in the company's future is reflected in the full subscription of the shares by the controlling entity, which is expected to stabilize control and support future growth [3][7][26] Group 2 - The funds raised will be used to supplement working capital and repay debts, which is crucial for the company's operational continuity and financial health [4][21][24] - The issuance will lead to an increase in total shares and net assets, potentially diluting earnings per share in the short term, with projections indicating a basic earnings per share of -0.37 before and after the issuance [16][18][21] - The company has committed to measures to mitigate the impact of dilution on immediate returns, ensuring that shareholder interests are protected [23][25][26] Group 3 - The issuance process adheres to relevant regulations, including the Securities Law and the Management Measures for the Issuance of Securities by Listed Companies [10][11][12] - The pricing of the shares is set at 6.55 yuan per share, which is 80% of the average trading price over the previous 20 trading days [9][10] - The company will ensure that the funds are managed and utilized according to established regulations, enhancing transparency and efficiency in fund usage [24][26]

Group 1 - The company Tianyu Bio-Technology Co., Ltd. plans to issue shares to a specific group, with the aim of raising funds to supplement working capital and repay debts [2][11][14] - The issuance will involve a maximum of 71,028,297 shares, which is capped at 30% of the company's total share capital prior to the issuance [13][15] - The share price is set at 6.55 RMB per share, which is not less than 80% of the average trading price over the 20 trading days prior to the pricing benchmark date [12][29] Group 2 - The issuance is characterized as a related party transaction, as the shares will be fully subscribed by Shanghai Daoyun Asset Management Co., Ltd., controlled by the company's actual controller, Luo Weiguo [10][15] - The company has a high debt ratio, with figures of 59.13%, 74.51%, 77.96%, and 75.91% at the end of the reporting periods, indicating significant financial pressure [10] - The funds raised will be used entirely for operational needs and debt repayment, which is expected to optimize the company's capital structure and enhance its sustainability [11][14] Group 3 - The company aims to enhance its control stability through this issuance, as the actual controller's stake will increase, reflecting confidence in the company's future [10][11] - The issuance is not expected to change the company's control structure, as the actual controller will maintain a significant voting power post-issuance [15] - The company has established a profit distribution policy to ensure transparency and stability in shareholder returns, aligning with regulatory guidelines [4][10]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次权益变动包含实际控制人罗卫国和史东伟一致行动关系解除、史东伟在 一定期限内放弃其所持全部公司股份所对应的表决权、罗卫国控制的企业导云资 产拟以现金认购公司 2025 年度向特定对象发行的股票。 综上所述，本次发行完成后，在不考虑其他因素可能导致股本数量变动的情 况下，按照本次发行预案上限测算，罗卫国直接和间接控制上市公司股份比例将 由 12.84%上升至 29.98%。 二、本次发行认购对象基本情况 （一）基本信息 （一）解除一致行动关系 前终止原《一致行动协议》，各方不再保持一致行动关系。解除一致行动关系后， 罗卫国与史东伟所持有的公司股份数量不再合并计算。 （二）放弃表决权 诺在一定期限内不可撤销的同意放弃其所持有的天域生物 32,338,800 股股份所对 应的提案权、表决权、召集权等全部非财产性权利，亦不得委托任何第三方行使。 史东伟表决权放弃后至表决权恢复前，其拥有表决权比例下降至 0.00%。 （三）向特定对象发行股票 导云资产与公司于 2025 ...

Core Viewpoint - Tianyu Biotechnology Co., Ltd. has convened its board meeting to approve the proposal for a private placement of A-shares, indicating the company's compliance with relevant regulations and its readiness to proceed with the issuance [1][2][3]. Board Meeting Details - The board meeting was held on August 25, 2025, with all nine directors present, and the resolutions passed were deemed legal and effective [1]. - The board approved the proposal for the company to issue A-shares to specific investors, confirming that the company meets the necessary conditions for such an issuance [2][3]. Issuance Proposal - The A-shares will have a nominal value of RMB 1.00 per share, and the issuance will be conducted through a private placement [2][3]. - The issuance price is set at RMB 6.55 per share, which is 80% of the average trading price over the previous 20 trading days [3][4]. - The total number of shares to be issued is capped at 71,028,297 shares, which is 30% of the company's total share capital prior to the issuance [4][6]. Use of Proceeds - The funds raised from this issuance will be used to supplement working capital and repay debts, with a total expected amount of up to RMB 526.7353 million [6][12]. - The company plans to utilize up to RMB 61.5 million of previously raised funds temporarily to support its working capital needs [6]. Lock-up Period and Trading - Shares acquired through this issuance will be subject to an 18-month lock-up period post-issuance [5][12]. - After the lock-up period, the shares will be listed for trading on the Shanghai Stock Exchange [6]. Related Transactions and Agreements - The issuance involves a related party transaction with Shanghai Daoyun Asset Management Co., Ltd., controlled by the company's actual controller, Mr. Luo Weiguo [3][12]. - The board has also approved a series of reports and agreements related to the issuance, including feasibility studies and the use of proceeds [9][10][12]. Future Plans and Authorizations - The board has proposed a three-year shareholder return plan for 2025-2027, which will be disclosed in detail [13]. - The company seeks authorization from the shareholders to allow the board to manage all matters related to the issuance, including adjustments based on market conditions [14][15].

证券代码：603717 证券简称：天域生物 公告编号：2025-070 天域生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 ? 股东大会召开日期：2025年9月11日 ? 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 (一)股东大会类型和届次 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 11 日 14 点 00 分 召开地点：上海市杨浦区国权北路 1688 号湾谷科技园 C4 幢二层 网络投票起止时间：自2025 年 9 月 11 日 至2025 年 9 月 11 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，1 ...

一、监事会会议召开情况 天域生物科技股份有限公司（以下简称"公司"）第四届监事会第三十六次 会议（以下简称"本次会议"）通知于 2025 年 08 月 19 日以电子邮件方式发出， 本次会议于 2025 年 08 月 25 日下午 14:00 以现场结合远程通讯的方式召开。本 次会议应到监事 3 人，实到监事 3 人。本次会议由公司监事会主席汪陈林先生主 持。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》、《公司 章程》和《监事会议事规则》等相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 证券代码：603717 证券简称：天域生物 公告编号：2025-062 天域生物科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：3 票同意，0 票反对，0 票弃权。 本次发行将全部采用向特定对象发行 A 股股票的方式进行，将在经过上海 证券交易所审核并取得中国证监会同意注册的批复有效期内选择适当时机向特 定对象发行。 本次会议审议并通过了如下议案： （一）《关于公司符合向特定对象发行 A ...

Core Viewpoint - The actual controller of Tianyu Biological has changed from a dual control by Luo Weiguo and Shi Dongwei to a single control by Luo Weiguo, following the signing of a termination agreement on August 25, 2025 [1][2] Group 1: Changes in Management and Control - Shi Dongwei has resigned as the president of the company to support Luo Weiguo in managing the company, while continuing to serve as the vice chairman of the board [2] - Shi Dongwei has signed a commitment not to seek control over Tianyu Biological and will not interfere with Luo Weiguo's control [2][3] - After the termination of the joint action relationship, Luo Weiguo holds 37.25 million shares, representing 12.84% of the voting rights [2] Group 2: Fundraising and Share Issuance - The company plans to issue shares to raise no more than 465 million yuan, with the funds used for working capital and debt repayment [2] - The share issuance will increase Luo Weiguo's direct and indirect control of the company from 12.84% to 29.98%, stabilizing his control [3] Group 3: Business Performance and Financial Health - Tianyu Biological has faced continuous losses over the past five years, with net profits of -157 million yuan, -215 million yuan, -312 million yuan, -462 million yuan, and -107 million yuan from 2020 to 2024 [3] - The company's debt ratio has remained high, reaching 75.91% as of the end of the first quarter of 2025 [3]

天域生物科技股份有限公司 简式权益变动报告书 上市公司名称：天域生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：天域生物 股票代码：603717 信息披露义务人：史东伟 住所/通讯地址：上海市杨浦区国权北路 1688 弄湾谷科技园 C4 幢莱蒙 B 座 202-203 室 股份变动性质：一致行动关系解除、表决权放弃 签署日期：2025 年 8 月 25 日 天域生物科技股份有限公司简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报告书》 及其他相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在天域生物科技股份有限公司中拥有权益的股 份变动情况。 截至本报告书签署之日，除本报告书披露的信 ...